Protalix BioTherapeutics (PLX) Total Current Liabilities (2010 - 2026)

Protalix BioTherapeutics' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $27.4 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 12.61% year-over-year to $27.4 million in Q1 2026; TTM through Mar 2026 was $27.4 million, a 12.61% increase from a year earlier, with the FY2025 full-year figure at $26.5 million, up 3.5% from the prior year.
• Total Current Liabilities advanced to $27.4 million in Q1 2026 per PLX's latest filing, from $26.5 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $58.0 million in Q2 2024 and bottomed at $21.9 million in Q3 2025.
• The 5-year median for Total Current Liabilities is $31.0 million (2022), against an average of $33.1 million.
• Across the five-year window, Total Current Liabilities sank 67.83% in 2022 and surged 150.86% in 2024, its largest moves.
• Year by year, Total Current Liabilities stood at $32.4 million in 2022, then jumped by 40.4% to $45.5 million in 2023, then slumped by 43.73% to $25.6 million in 2024, then climbed by 3.5% to $26.5 million in 2025, then grew by 3.28% to $27.4 million in 2026.
• Per Business Quant, the three latest PLX Total Current Liabilities figures stand at $27.4 million (Q1 2026), $26.5 million (Q4 2025), and $21.9 million (Q3 2025).